Duvelisib was the 2nd PI3K inhibitor permitted via the FDA, also dependant on a section III randomized demo.130 The efficacy and basic safety profile of the drug seem equivalent with those of idelalisib, if not marginally beneficial. Concerning different BTK inhibitors, there are lots of solutions in development, but only acalabrutinib is accepted